

TARO PHARMACEUTICAL INDUSTRIES LTD
Form SC 13G/A
July 12, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Taro Pharmaceutical Industries Ltd.
(Name of Issuer)

Common
(Title of Class of Securities)

M8737E108
(CUSIP Number)

July 2, 2004
(Date of Event Which Requires Filing of the Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

- Rule 13d-1 (b)
 Rule 13d-1 (c)
 Rule 13d-1 (d)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).

CUSIP No. M8737E108

13G

Page 2 of 5 Pages

- 1) NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Neuberger Berman, Inc.
061523639
Neuberger Berman, LLC
13-5521910

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13G/A

- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /___/
(b) /X/
- 3) SEC USE ONLY
- 4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

- 5) SOLE VOTING POWER
30,925
- 6) SHARED VOTING POWER
2,397,732
- 7) SOLE DISPOSITIVE POWER
0
- 8) SHARED DISPOSITIVE POWER
3,105,657
- 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,105,657
- 10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
2,150
- 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
10.74
- 12) TYPE OF REPORTING PERSON*
BD/IA

CUSIP No. M8737E108

13G

Page 2A of 5 Pages

- 1) NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Neuberger Berman Genesis Fund
133697433

- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /___/
(b) /X/
- 3) SEC USE ONLY
- 4) CITIZENSHIP OR PLACE OF ORGANIZATION
USA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

- 5) SOLE VOTING POWER
0

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13G/A

- 6) SHARED VOTING POWER
2,341,432
- 7) SOLE DISPOSITIVE POWER
0
- 8) SHARED DISPOSITIVE POWER
2,341,432
- 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,341,432
- 10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
- 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.09
- 12) TYPE OF REPORTING PERSON*
IV

CUSIP No. M8737E108 13G Page 3 of 5 Pages

- Item 1. (a) Name of Issuer:
Taro Pharmaceutical Industries Ltd.
- Item 1 (b) Address of Issuer's Principal Executive Offices:
Five Skyline Drive, Hawthorne, NY 10532
- Item 2. (a) Name of Person Filing:
Neuberger Berman, Inc.
Neuberger Berman, LLC.
Neuberger Berman Management Inc.
Neuberger Berman Genesis Fund
- Item 2 (b) Address of Principal Business Office:
605 Third Ave., New York, NY, 10158-3698
- Item 2 (c) Citizenship:
USA
- Item 2 (d) Title of Class of Securities:
Common
- Item 2 (e) CUSIP Number:
M8737E108
- Item 3. (g) /X/ Parent holding company, in accordance with 240.13d-1
(b) (ii) (G)
- Item 4. Ownership:
(a) Amount Beneficially Owned:
3,105,657

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13G/A

(b) Percent of Class:

10.74

CUSIP No. M8737E108

13G

Page 4 of 5 Pages

(c) Number of Shares as to which such person has:

(I) Sole Power to vote or to direct the
vote: 30,925

(II) Shared Power to vote or to direct the
vote: 2,397,732

(III) Sole Power to dispose or to direct the disposition
of: 0

(IV) Shared Power to dispose or to direct the disposition
of: 3,105,657

Item 5. Ownership of Five Percent or Less of a Class:

N/A

Item 6. Ownership of More than Five Percent on Behalf of Another:

Neuberger Berman, LLC is deemed to be a beneficial owner for purpose of Rule 13(d) since it has shared power to make decisions whether to retain or dispose of, and in some cases the sole power to vote the securities of many unrelated clients. Neuberger Berman, LLC does not, however, have any economic interest in the securities of those clients. The clients are the actual owners of the securities and have the sole right to receive and the power to direct the receipt of dividends from or proceeds from the sale of such securities.

Employee(s) of Neuberger Berman, LLC own 2,150 shares. Employee(s) own these shares in their own personal securities accounts. Neuberger Berman, LLC disclaims beneficial ownership of these shares since; these shares were purchased with each employee(s) personal funds and each employee has exclusive dispositive and voting power over the shares held in their respective accounts.

With regard to the shares set forth under Item 4.(c)(II), 2,341,432 shares or 8.09% of the outstanding are beneficially owned by Neuberger Berman Genesis Fund Portfolio, a series of Equity Managers Trust. Neuberger Berman, LLC and Neuberger Berman Management Inc. are deemed to be beneficial owners of these shares for purposes of Rule 13(d) since they both have shared power to make decisions whether to retain or dispose of the securities. Neuberger Berman, LLC and Neuberger Berman Management Inc. serve as sub-adviser and investment manager, respectively, of Neuberger Berman Genesis Fund Portfolio, which holds such shares in the ordinary course of its business and not with the purpose nor with the effect of changing or influencing the control of the issuer.

With regard to the balance of the shares set forth under Item 4.(c)(II), Neuberger Berman, LLC and Neuberger Berman Management Inc. are deemed to be the beneficial owners for the purposes of Rule 13(d), since they have power to make decisions whether to retain or dispose of securities held by

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13G/A

Neuberger Berman's various other Funds. Neuberger Berman, LLC is the sub-advisor to the aforementioned Funds.

No other Neuberger Berman, LLC advisory client has an interest of more than 5% of the issuer.

It should be further noted that the share calculation under item 4.(c)(IV) is derived from a total combination of the shares set forth under Item 4.(c)(I and II). The remaining balance of shares, if any, are for individual client accounts over which Neuberger Berman, LLC has shared power to dispose.

CUSIP No. M8737E108

13G

Page 5 of 5 Pages

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

Neuberger Berman, Inc. makes this filing pursuant to Rule 13d-1(b)(ii)(G) since it owns 100% of both Neuberger Berman, LLC and Neuberger Berman Management, Inc. and does not own over 1% of the issuer.

Neuberger Berman, LLC, as investment advisor and broker/dealer with discretion.

Neuberger Berman Management Inc. as investment advisor to a Series of Public Mutual Funds.

Item 8. Identification and Classification of Members of the Group:
N/A

Item 9. Notice of Dissolution of Group:
N/A

Item 10. Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature:

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

In addition, the undersigned hereby agree that the Schedule 13G filed herewith is filed jointly pursuant to Rule 13d-1(f)(1) of the Securities Exchange Act of 1934, as amended, on behalf of each of them.

Date: July 7, 2004

By: _____
Kevin Handwerker
General Counsel
Neuberger Berman, Inc.
Neuberger Berman, LLC.

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13G/A

By: _____
Peter Sundman
President and Director
Neuberger Berman Management Inc.

By: : _____
Peter Sundman
Chairman of the Board, Chief Executive
Officer and Trustee
Neuberger Berman Genesis Fund,
a Series of Equity Managers Trust